Formulation for administration of RNA

US11318195B2 · kind B2 · utility

Assignees

• BIONTECH SE · DE
• TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz · DE

Inventors

• Ugur Sahin · Mainz, DE
• Heinrich Haas · Mainz, DE
• Annette Vogel · Mainz, DE
• Daniel Zucker · Palo Alto, US
• Stephanie Erbar · Mainz, DE
• Kerstin Walzer · Seeheim-Jugenheim, DE
• Anne Schlegel · Mainz, DE
• Sebastian Hörner · Mainz, DE
• Sebastian Kreiter · Mainz, DE
• Mustafa Diken · Mainz, DE
• Jorge Moreno Herrero · Mainz, DE

Key dates

• Filing date: Jul 14, 2017
• Grant date: May 3, 2022
• Expiry date: Oct 8, 2037

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2760/16171
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to compositions comprising polyplex formulations for delivery of RNA to a target organ or a target cell after parenteral administration, in particular after intramuscular administration. More precisely, the present invention relates to formulations for administration of RNA such as self-replicating RNA, in particular by intramuscular injection. In more detail, the formulations comprise polyplex particles from single stranded RNA and a polyalkyleneimine. The RNA may encode a protein of interest, such as a pharmaceutically active protein. Furthermore, the present invention relates to pharmaceutical products, comprising said RNA polyplex formulations for parenteral application to humans or to animals. The present invention relates as well to manufacturing of such pharmaceutical products, comprising, optionally, steps of sterile filtration, freezing and dehydration.